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ALOX5 is implicated in chronic myeloid leukaemia development in mouse leukaemic stem cells, but its 
importance in human chronic myeloid leukaemia is unknown. Functional ALOX5 was assessed using 
an leukotriene-B4 ELISA and ALOX5 and leukotriene-B4 receptor 1 mRNA expression was determined 
via a TaqMan gene expression assay. leukotriene-B4 receptor 1 and 5-LOX protein levels were 
assessed by cell surface flow cytometry analysis.  At diagnosis ALOX5 was below normal in both blood 
and CD34+ stem cells in all patients. On treatment initiation, ALOX5 levels increased in all patients 
except those who were destined to progress subsequently to blast crisis.  leukotriene-B4 levels were 
increased despite low ALOX5 expression, suggesting that the arachidonic acid pathway is functioning 
normally up to the point of leukotriene-B4 production.  However, the leukotriene-B4 receptor protein 
in newly diagnosed patients was significantly lower than after a period of treatment (p<0.0001). The 
low level of leukotriene-B4 receptor 1 at diagnosis explains the down-regulation of ALOX5. In the 
absence of leukotriene-B4 receptor 1, the arachidonic acid pathway intermediates (5-HEPTE and LTA4) 
negatively regulate ALOX5.  ALOX5 regulation is aberrant in chronic myeloid leukaemia patients and 
may not be important for the development of the disease. Our data suggest caution when 









Chronic myeloid leukaemia (CML) is a malignant disease of a primitive haematological cell, 
characterised by inappropriate expansion of myeloid cells. Although the disease is readily controlled 
by imatinib, approximately one third of patients will eventually fail treatment,1, 2 and a significant 
proportion of these will progress towards blast crisis which is usually fatal. However, the factors that 
contribute towards CML growth and progression are not well understood. Recently, Chen et al3 
reported that Arachidonate 5-lipoxygenase (ALOX5) is up-regulated in mouse leukaemic stem cells, 
and this up-regulation is not inhibited by imatinib treatment.  Furthermore, mice transplanted with 
ALOX5 deficient BCR-ABL1 positive bone marrow cells were resistant to CML induction. ALOX5 
deficiency had no effect on the growth of BCR-ABL1 negative cells, suggesting that it may be essential 
for malignant but not normal haemapoietic stem cell growth, through an unknown mechanism.  
 
The ALOX5 gene encodes a member of the lipoxygenase gene family and plays a role in the synthesis 
of leukotrienes from arachidonic acid (Figure 1).  ALOX5 catalyses the conversion of arachidonic acid 
to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HEPTE), and subsequently to the 
allylic epoxide 5(S)-trans-7,9-trans-11,14-cis-eicosatetraenoic acid (leukotriene A4/LTA4).  LTA4 is 
unstable and is converted to LTB4 which is more stable. 5-HEPTE and LTA4 negatively regulate ALOX5 
expression; positive regulation of ALOX5 occurs when LTB4 binds to its receptor LTB4R1 (also known 
as BLT1) to mediate its positive feedback on ALOX5.4-9 
 
The role of ALOX5 in human CML is unknown. The hypothesis proposed in this study was that CML 
cells have high levels of ALOX5 and that the level of ALOX5 predicts a patient’s response to imatinib 






Sample collection: Blood samples were collected from 48 patients at initial chronic phase diagnosis 
and at 3, 6 and 12 months following the commencement of imatinib treatment.  Plasma and total 
leukocytes were prepared. Samples were enriched for CD34+ cells using CliniMACS (Miltenyi Biotec, 
Surrey, UK) according to the manufacturer's instructions. The study was approved by the Liverpool 
Central Research Ethics Committee and all patients gave informed consent. Patient characteristics are 
shown in Table 1. Peripheral blood from healthy volunteers were used as normal controls (n=10)  
 
 
Clinical response: Following 12 months of imatinib treatment, patients were stratified into three 
clinical outcomes: 
 Responders – Patients who achieve a complete cytogenetic response CCR defined as no 
Philadelphia positive metaphases amongst at least 20 marrow metaphases. In some cases 
serial cytogenetic data were not available and achievement of CCR is based on a BCR-
ABL1/ABL1 transcript ratio of < 1%, which we have previously shown to be tightly correlated 
with cytogenetically defined CCR. 10  
 Non-responders – Patients who had achieved a complete haematological response but not a 
complete cytogenetic response and who had not progressed. 
 Blast crisis – patients who presented in chronic phase but who subsequently progressed into 
blast crisis. 
 
Plasma preparation: 5ml of peripheral blood was collected into EDTA, and centrifuged at 770g for 15 
minutes.  Plasma was collected from samples, aliquoted and stored at -20°C prior to use.   
 
Leukotriene B4 ELISA: LTB4 assay was performed according to the manufacturer’s protocol 
(Cambridge Biosciences, Cambridge, UK). Briefly 100μl of the specific standard, sample or assay buffer 
was added in duplicate to appropriate wells of a 96-well plate and a further 50μl of assay buffer to the 
negative control wells.  50μl of LTB4 conjugate and 50μl of LTB4 antibody, supplied in the kit, were 
added to the appropriate wells.  The plate was incubated at room temperature, with shaking, for 2 
hours.  Following incubation the plate was washed three times with wash solution (provided in the 
kit). 5μl of conjugate was added to the total activity wells, followed by 200μl of pNpp substrate 
solution to every well.  The plate was incubated at 37°C with shaking, for 2 hours.  50μl of 2M HCl was 
then added to all wells.  The absorbance was immediately read at 405nm using a BioTeK μQuant plate 
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reader. The mean optical density of the negative controls was subtracted from the optical density 
reading of all wells to eliminate “background noise.”    
 
ALOX5 and LTB4R1 expression: qRT-PCR was performed using cDNA from either total leukocytes or 
purified CD34+ cells. Pre-designed TaqMan real time PCR assays were used for ALOX5 
Hs01095330_m1, BLT1 (LTB4R1) Hs019388704_s1 and GAPDH Hs99999905_m1 (Applied Biosciences, 
UK). In evaluating the mRNA expression data, the comparative Ct method was used, with the 2-ΔΔCt 
formula to achieve results for relative quantification (RQ).10 A pool of cDNA from 4 normal individuals 
was used as calibrator and all the samples were normalised to GAPDH. The RQ Manager software 
supported by the ABI Prism 7900HT System was used for data analysis.  
 
Measurement of LTB4 receptor 1 (BLT1): 5ml of peripheral blood was collected into EDTA from CML 
patients attending the CML clinic. Samples were processed within 4 hours of the sample being taken 
and cells were used fresh. Briefly, erythrocytes were depleted using red cell lysis buffer ((0.1M 
ammonium chloride, 10mM sodium bicarbonate and 1.3mM EDTA (Sigma-Aldrich, Dorset, UK).  Total 
leukocytes were then incubated with Leukotriene B4
 
Receptor 1 (BLT1/LTB4R1) (R&D systems, 
Abingdon, UK.) and anti -mouse IgG1 antibody (BD) as the control antibody, in the dark for 30 minutes 
with shaking. Cells were then washed in PBS containing 0.5% BSA and analysed by FACS. 
 
Measurement of ALOX5 protein by FACS: 5-lipoxygenase (5-Lox) protein was assessed by FACS using 
the method previously described using 5-LOX antibody (Santa Cruz Biotechnology, California, USA) 






ALOX5 mRNA expression and clinical outcome 
In order to determine whether ALOX5 expression was elevated in CML patients, and if the levels were 
related to clinical outcome, ALOX5 expression was measured at diagnosis (chronic phase) and 
following 3, 6 and 12 months of imatinib treatment. Patients’ details are shown in table 1. At diagnosis 
the expression level of ALOX5 was below the level observed in normal healthy volunteers cDNA pool.  
This was the case in responders, non-responders and those who subsequently progress to blast crisis, 
as defined in the design and methods section (Figure 2). No difference was seen between patients 
according to their Sokal score (data not shown). In the responder cohort once imatinib treatment had 
commenced, the expression level of ALOX5 increased and remained high throughout treatment. The 
increase in ALOX5 expression compared with diagnosis was statistically significant at 3, 6 and 12 
months (p=0.003, p=<0.001 and p=0.024 respectively). These data suggest that ALOX5 expression in 
patients who subsequently achieve a CCR is restored to a level observed in the normal calibrator pool 
upon treatment (Figure 2A). A similar trend in ALOX5 expression was observed in the non-responder 
group (Figure 2B), with ALOX5 expression increasing once treatment had commenced. Again the 
increase in ALOX5 expression compared with diagnosis was statistically significant at 3, 6 and 12 
months (p=0.008, p=0.03 and p=0.013 respectively). Conversely, in patients destined to subsequently 
progress to blast crisis, imatinib treatment failed to increase ALOX5 expression (Figure 2C).  
 
These data suggest that a failure to increase ALOX5 expression following three months of imatinib 
treatment may indicate a higher risk of disease progression (Figure 2C).  No difference in ALOX5 
expression was observed at diagnosis between those patients destined to progress to blast crisis and 
the responder and non-responder groups, suggesting that ALOX5 expression at diagnosis is not 
predictive of the outcome of imatinib treated patients. 
 
When the same experiment was repeated on diagnostic CD34+ stem cells (from the same patients), 
no difference in ALOX5 expression was observed between responders and non-responders.  ALOX5 
expression was lower in CD34+ cells than in total leukocytes when comparing results in figure 2 A and 
D, although similar overall results were obtained, confirming that ALOX5 is down-regulated in CML 
patients in both CD34+ and chronic phase MNC (Figure 2, panels A and D,  p=0.01). 
 
To determine whether 5-LOX protein levels were a function of ALOX5 gene expression, 5-LOX protein 
expression was assessed by FACS. As patients respond to imatinib treatment and achieve a major 
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molecular response (MMR), there is a trend for an increase in the amount of detectable ALOX5 protein 
(Figure 2E); this is consistent with the increase in mRNA expression observed in Figure 2A-C. 
 
ALOX5 function - LTB4 levels in CML patients 
Plasma levels of LTB4 can be used as a marker of ALOX5 functional activity (as previously described by 
Chen et al3).  LTB4 levels were measured at diagnosis, three and six months post imatinib treatment 
in 27 patients of known subsequent clinical outcome (18 responders, 7 non-responders and 2 patients 
whom subsequently progressed to blast crisis, Figure 3A). LTB4 levels increased in all three patient 
groups following imatinib treatment. At diagnosis the LTB4 level in patients destined to progress to 
blast crisis was the lowest of the three patient groups. Conversely, once imatinib treatment 
commenced the LTB4 level increased to the highest level compared to the other two clinical groups 
(Figure 3A). The levels of LTB4 in the CML patients were in general higher than normal; this may 
indicate an accumulation of LTB4 and a potential block in the arachidonic acid pathway. 
 
Since LTB4 levels increased in all patients assessed, it was necessary to confirm whether this was a 
direct physiological response to imatinib treatment, or if it was due to the disease. To address this 
issue, MNC from five healthy volunteers were treated with 5µM imatinib for 24 hours and the changes 
in LTB4 levels were measured. No significant difference was observed between the untreated and 
imatinib treated normal samples, thus suggesting that changes in LTB4 observed in CML patients may 
be attributed to the leukaemia and not as a physiological response to imatinib treatment (Figure 3B).  
 
ALOX5 function was assessed using samples from patients diagnosed in chronic phase and from 
patients actually in blast crisis. LTB4 levels were found to be elevated in samples taken at blast crisis 
compared to chronic phase samples, but this difference was not statistically significant. The observed 
increase in LTB4 observed coincided with a decrease in ALOX5 expression as shown is figure 2C. 
 
LTB4 receptor 1 (BLT1) is low at diagnosis 
The original hypothesis proposed in this study was that CML patients would have high levels of ALOX5.  
The data presented thus far are in opposition to both this hypothesis and the study presented by Chen 
et al,3  which demonstrated that mice transplanted with BCR-ABL1 positive bone marrow cells lacking 
the ALOX5 gene were resistant to the induction of CML, suggesting that ALOX5 was essential for the 
induction and development of CML.3  However, that study was performed using a mouse model, and 
the experiments have not yet been carried out on human CML samples, which could explain the 
discrepancies between the present data and those of Chen et al.3 In order to further explain the 
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differences between the two studies, the LTB4 pathway was interrogated further. Figure 1 
demonstrates the arachidonic acid metabolism pathway. Prior to conversion to LTB4, arachidonic acid 
is converted into two intermediate products, 5-HEPTE and then LTA4. Both 5-HEPTE and LTA4 
negatively regulate ALOX5 expression, while LTB4 is known to positively regulate ALOX5 expression.12 
In order for LTB4 to mediate its positive effect on ALOX5 expression it must bind to the LTB4 receptor.  
 
In the CML clinical samples investigated it is apparent that ALOX5 expression is suppressed below 
normal. Furthermore, the LTB4 levels in the CML samples were elevated compared to normal healthy 
controls, suggesting an accumulation of LTB4. Since LTB4 needs to bind to its receptor LTB4R1 to 
positively regulate ALOX5 expression, these data suggest that LTB4R1 expression or function may be 
abnormal in CML. 
 
LTB4R1 protein expression was measured by cell surface FACS analysis. LTB4R1 protein was found to 
be low in newly diagnosed chronic phase CML samples compared to normal (p=<0.0001, Figure 4A). 
LTB4R1 protein was even lower in a blast crisis sample. We next compared the levels of LTB4R1 protein 
in patients being treated by imatinib and stratified these data by the patients BCR-ABL1/ABL1 
percentage. LTB4R1 protein levels were lower than normal in those patients partially responding to 
imatinib treatment (defined as a BCR-ABL1/ABL1 ratio of 1-10%) (p=0.04). LTB4R1 levels increased 
from the diagnosis level once treatment had commenced. Patients partially responding and those 
patients whom had achieved a complete cytogenetic response (defined as a BCR-ABL1/ABL1 ratio of 
<1%13) had significantly higher levels of LTB4R1 protein compared to the level observed at diagnosis 
(p=0.02 and p=<0.0001, respectively). These data suggest that there is an inverse relationship between 
LTB4R1 protein and BCR-ABL1 mRNA expression.  LTB4R1 protein is very low at diagnosis but increases 
towards normal as the BCR-ABL1 mRNA expression decreases. 
 
LTB4R1 mRNA expression 
LTB4R1 mRNA expression was found to be low in chronic phase diagnostic samples compared to 
patients who had received 12 months of imatinib treatment (Figure 4B). In the responder group the 
LTB4R1 expression increased more than in the non-responder group, although this was not statistically 
significant. When LTB4R1 mRNA expression was assessed in samples from patients in blast crisis at the 
time of sampling, LTB4R1 mRNA expression was much lower than the diagnostic chronic phase group 
and the 12 month treatment samples. LTB4R1 mRNA expression was not statistically significant at 




As patients progress to blast crisis, ALOX5 gene expression is suppressed, possibly due to an 
accumulation of pathway intermediates (5-HEPTE and LTA4) and a decrease in LTB4R1. This idea is 
supported by the LTB4R1 protein data and the accumulation of LTB4 in blast crisis. LTB4R1 mRNA 
expression was also assessed in CD34+ stem cells taken at diagnosis (Figure 4C). No difference in 





The identification of proteins which discriminate leukaemic from normal stem cells is a challenging 
concept. Successful identification and therapeutic targeting of leukaemic stem cells remains the 
ultimate goal in eradicating CML. 
 
The present data suggest that although ALOX5 has been identified as being essential for the 
development of CML in mice, this is not the case in human CML. Initial assessment of ALOX5 
expression pre and post imatinib treatment in human CML demonstrated that ALOX5 was down-
regulated below normal, unlike the mouse model of CML which showed that ALOX5 was up-regulated.  
Following imatinib treatment, ALOX5 mRNA expression increased in the responder and non-responder 
groups. In patients who subsequently progressed to blast crisis, no change in ALOX5 expression was 
observed. The failure to increase ALOX5 expression following 3 months of imatinib treatment may 
identify patients at high risk of disease progression. However whether changes in ALOX5 expression 
offer any additional value beyond those obtained from measuring early cytogenetic or molecular 
responses remains unknown and would need to be tested further as part of a clinical trial.  
 
ALOX5 function was assessed by measuring plasma LTB4. LTB4 was found to increase in all three 
groups of patients following imatinib treatment. LTB4 was also found to be increased in blast crisis 
compared to chronic phase. These data suggest that the arachidonic acid pathway (Figure 1) is 
functionally active to the point of LTB4 production.  
 
To determine the differences between the ALOX5 pathway observed in mice and the clinical samples 
studied, the LTB4 receptor (BLT1) was investigated. LTB4 acts by binding to LTB4R1 in order to mediate 
its positive role on ALOX5. At diagnosis of CML patients had very low levels of LTB4R1 protein 
compared to normal samples. Following imatinib treatment LTB4R1 levels increased towards normal 
and in a case in blast crisis LTB4R1 protein was further suppressed. Using the Bayesian model 
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averaging (BMA) method on a large microarray data set Radich et al14 identified six genes that 
discriminate between early chronic phase, late chronic phase, accelerated phase and blast crisis, one 
of these genes was LTB4R1. The authors found this to be down-regulated during blast crisis which is 
in agreement with our data. These findings help to explain the data seen in CML patients. At diagnosis 
of CML, ALOX5 gene expression was found to be suppressed and there was an accumulation of LTB4. 
The accumulation of LTB4 is likely due to lack of the LTB4 receptor. A lack of LTB4R1 allows the namely 
5-HEPTE and LTA4 intermediates of the pathway to suppress ALOX5 gene expression, and thus LTB4 
accumulates as it has no receptor to bind to. Following imatinib treatment LTB4R1 protein increases; 
thus LTB4 can bind to its receptor and positively regulate ALOX5 as demonstrated by an increase in 5-
LOX protein and gene expression. 
 
In patients with atherosclerosis the binding of LTB4 to LTB4R1 induces the rapid phosphorylation of 
mitogen activated protein kinases (MAPK, ERK1/2 and JNK1/2) and PI3K/AKT, and also increases NF-
κB activation,15 which are  all targets of BCR-ABL1. It is therefore interesting to speculate that CML 
cells attempt to switch off excessive signalling via these pathways by down-regulating LTB4R1 in order 
to try and maintain cellular homeostasis.  
 
Our conclusions are based on work carried out using both MNC and CD34+ cells. We would like to 
extend these observations by assessing ALOX5 and LTB4R1 expression in primitive CD34+CD38- or 
CD34+CD38-CD90+ stem progenitor cells, but like most laboratories we do not have access to such 
sorted primitive sub populations. We hope these can be the subject of future studies. 
 
In conclusion, it is apparent that two different pathways exist with regards to ALOX5 between the CML 
mouse model and CML patients. This accounts for the difference between the clinical samples studied 
herein and the results of the Chen et al3 paper. These data suggest caution when extrapolating mouse 
model data into human CML.  
 
ACKNOWLEDGEMENTS 
We would like to thank the Alison Holcroft, Rachael Fowler and Andrea Davies for their help and 
support during this project.  AG was supported by a generous donation in memory of a CML patient. 
 
AUTHORSHIP AND DISCLOSURES 
CML and RJH contributed equally to this study and share first authorship. 
11 
 
CML, RJH and REC designed the study and wrote the manuscript. 
CML, AG, and EM performed the laboratory work for this study. 





1. Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH, et al. A 
population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than 
in clinical trials. Leukemia. 2008;22(10):1963-6. 
2. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. 
Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of 
Sustained Responses in an Intention-to-Treat Analysis. J Clin Oncol. 2008;26(20):3358-63. 
3. Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem 
cells and prevents chronic myeloid leukemia. Nat Genet. 2009;41(7):783-92. 
4. Manev H, Manev R. 5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene 
polymorphisms as factors in vascular pathology and Alzheimer's disease. Medical 
Hypotheses. 2006;66(3):501-3. 
5. Chen Y, Li D, Li S. The Alox5 gene is a novel therapeutic target in cancer stem cells 
of chronic myeloid leukemia. Cell Cycle. 2009;8(21):3488-92. 
6. Yokomizo T, Uozumi N, Takahashi T, Kume K, Izumi T, Shimizu T. Leukotriene A4 
hydrolase and leukotriene B4 metabolism. J Lipid Mediat Cell Signal. 1995;12:321-32. 
7. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, et al. 
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-
asthma treatment. Nat Genet. 1999;22(2):168-70. 
8. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, et al. Arachidonate 5-
Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and Atherosclerosis. N Engl J 
Med. 2004;350(1):29-37. 
9. Hoque A, Lippman SM, Wu T, Xu Y, Liang ZD, Swisher S, et al. Increased 5-
lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a 
potential target for prevention. Carcinogenesis. 2005;26(4):785-91. 
10. Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Serial monitoring of BCR-
ABL by peripheral blood real-time polymerase chain reaction predicts the marrow 
cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol. 
2002;118(3):771-7. 
11. Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, et al. 
Chronic myeloid leukaemia patients with the e13a2 BCR-ABL fusion transcript have inferior 
responses to imatinib than e14a2 patients. Haematologica. 2009;94(10):1362-7  
12. Lyons MA, Wittenburg H. Susceptibility to cholesterol gallstone formation: Evidence 
that LITH genes also encode immune-related factors. Biochim Biophys Acta. 
2006;1761(10):1133-47. 
13. Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Serial monitoring of BCR-
ABL by peripheral blood real-time polymerase chain reaction predicts the marrow 
cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol. 
2002;118(3):771-7. 
14. Oehler VG, Yeung KY, Choi YE, Bumgarner RE, Raftery AE, Radich JP. The 
derivation of diagnostic markers of chronic myeloid leukemia progression from microarray 
data. Blood. 2009;114(15):3292-8. 
15. Sánchez-Galán E, Gómez-Hernández A, Vidal C, Martín-Ventura JL, Blanco-Colio 
LM, Muñoz-García B, et al. Leukotriene B4 enhances the activity of nuclear factor-κB 






Table 1. Patient characteristics. 
 
    Sokal score 
 No. patients M/F Mean age (range) Low Intermediate High Unknown 
Responders 25 11/14 43 (19-60) 15 3 5 2 
Non-responders 17 8/9 49 (23-67) 4 3 7 3 
Blast crisis 6 5/1 37 (24-59) 1 2 2 1 






Table 1. Patient characteristics  
Figure 1.  Arachidonic acid metabolism pathway.  
5-LOX is encoded by the ALOX5 gene and is activated by the enzyme FLAP. Arachidonic acid is 
converted to 5-HEPTE by 5-LOX which is further converted to LTA4 by 5-LOX. Both 5-HEPTE and LTA4 
negatively regulate ALOX5 expression. LTA4 is unstable and is further converted to LTB4. The binding 
of LTB4 to its receptor LTB4R1 positively regulates ALOX5 expression. 
 
Figure 2. ALOX5 expression  
Panel A: ALOX5 expression levels in the responder group (n=25). Panel B: ALOX5 expression levels in 
the non-responders group (n=17).  Panel C: ALOX5 expression levels in patients destined to progress 
into blast crisis (n=6). Panel D: ALOX5 expression levels in CD34+ cells taken at diagnosis and stratified 
by the patients’ eventual clinical response. The normal level was determined using four healthy 
volunteers (n=6). Panel E: 5-LOX protein expression. 5-LOX protein was assessed by FACS using fresh 
leukocytes (n=9). 5-LOX expression is higher in CML patients in major molecular response as 
determined by qRT-PCR.    
 
Figure 3.  LTB4 levels following imatinib treatment.  
Panel A. Mean plasma LTB4 levels of 27 patients stratified by clinical outcome; 18 responders, 7 non-
responders and 2 blast crisis.  Samples were taken during chronic phase at diagnosis, 3 and 6 months 
after commencement of imatinib treatment.  Normal level was determined using plasma from 15 
healthy volunteers.  Panel B. MNC from five healthy volunteers were treated with 5µM imatinib for 
24 hours and the changes in LTB4 levels were measured. No significant difference was observed 
between the untreated and imatinib treated normal samples. 
 
Figure 4. LTB4 (BLT1) receptor  expression.  
Panel A: LTB4R1 surface expression was measured in newly diagnosed chronic phase CML patients 
(n=5), a patient in blast crisis (n=1), patients currently responding to imatinib treatment (n=6), patients 
in CCR (n=10) and healthy volunteers (n=10). LTB4R1 cell surface expression was low in newly 
diagnosed chronic phase CML patients compared to patients responding to treatment or healthy 
volunteers. P values denoted with *refer the comparison made with normal blood. Panel B: LTB4R1 
mRNA expression was measured in newly diagnosed chronic phase CML patients (n=24), patients 
treated with imatinib for twelve months who achieved a CCR (n=10) and non-responders (n=8), as well 
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as patients who were in blast crisis (n=6). Panel C: LTB4R1 mRNA expression in diagnostic CD34+ cells 
stratified by the patient’s clinical outcome.  
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